Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

AnaptysBio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, AUG. 06, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

ANAPTYS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, JUNE 03, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT INVESTIGATIONAL ROSNILIMAB, A DEPLETER AND AGONIST TARGETING PD-1+ T CELLS, DEMONSTRATED A BEST-IN-DISEASE PROFILE IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA). IN THE ROBUST, GLOBAL 424-PATIENT PHASE 2B TRIAL, ROSNILIMAB ACHIEVED JAK-LIKE EFFICACY ON MULTIPLE CLINICALLY MEANINGFUL MEASURES, INCLUDING LOW DISEASE ACTIVITY (LDA) AND REMISSION ON THE CLINICAL DISEASE ACTIVITY INDEX (CDAI), AS WELL AS ACR70 RESPONSE, OVER A SIX-MONTH PERIOD. FURTHERMORE, RESPONSES WERE THEN DURABLE FOR AT LEAST TWO MONTHS OFF DRUG. ROSNILIMAB WAS SAFE AND WELL TOLERATED, PARTICULARLY WHEN COMPARED TO STANDARD OF CARE BIOLOGICS OR JAKS.

ANAPTYS ANNOUNCES POSITIVE ROSNILIMAB DATA UPDATED THROUGH SIX MONTHS IN ROBUST PHASE 2B TRIAL IN RA

SAN DIEGO, MAY 27, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, WILL HOST AN INVESTOR CALL AND LIVE WEBCAST TO REVIEW UPDATED DATA FROM THE GLOBAL PHASE 2B RENOIR CLINICAL TRIAL OF INVESTIGATIONAL ROSNILIMAB, A DEPLETER AND AGONIST TARGETING PD-1+ T CELLS, FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS ON TUESDAY, JUNE 3, 2025, AT 4:15PM ET / 1:15PM PT.

ANAPTYS TO ANNOUNCE UPDATED DATA FROM PHASE 2B TRIAL OF ROSNILIMAB, A PD-1 DEPLETER AND AGONIST, FOR RHEUMATOID ARTHRITIS ON JUNE 3, 2025

SAN DIEGO, MAY 05, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

ANAPTYS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, MARCH 24, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED A STOCK REPURCHASE PLAN UNDER WHICH THE COMPANY MAY REPURCHASE UP TO $75,000,000 OF THE COMPANY'S OUTSTANDING COMMON STOCK, PAR VALUE $0.001 PER SHARE.

ANAPTYS ANNOUNCES STOCK REPURCHASE PLAN

SAN DIEGO, FEB. 27, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS, AND/OR OTHER MEMBERS OF ITS EXECUTIVE LEADERSHIP TEAM, ARE SCHEDULED TO PARTICIPATE IN MULTIPLE UPCOMING INVESTOR CONFERENCES: TD COWEN 45 TH ANNUAL HEALTHCARE CONFERENCE,BOSTON, MA FORMAT  FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS DATE AND TIME TUESDAY, MAR. 4, 2025AT1:10PM ET/10:10AM PT LEERINK PARTNERS 2025 GLOBAL HEALTHCARE CONFERENCE,MIAMI, FL FORMAT  FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGS DATE AND TIME TUESDAY, MAR. 11, 2025AT10:40AM ET/7:40AM PT BARCLAYS 27 TH ANNUAL GLOBAL HEALTHCARE CONFERENCE,MIAMI, FL FORMAT  PRESENTATION AND ONE-ON-ONE INVESTOR MEETINGS DATE AND TIME WEDNESDAY, MAR. 12, 2025AT8:30AM ET/5:30AM PT LIVE WEBCASTS OF THE FIRESIDE CHATS AND PRESENTATION WILL BE AVAILABLE ON THE INVESTOR SECTION OF THE ANAPTYS WEBSITE ATHTTP://IR.ANAPTYSBIO.COM/EVENTS. REPLAYS OF THE WEBCASTS WILL BE AVAILABLE FOR AT LEAST 30 DAYS FOLLOWING THE EVENTS.

ANAPTYS ANNOUNCES PARTICIPATION IN MARCH INVESTOR CONFERENCES

ANNOUNCED ROSNILIMAB, A PD-1 DEPLETER AND AGONIST, ACHIEVED POSITIVE RESULTS FROM PHASE 2B RHEUMATOID ARTHRITIS (RA) TRIAL AND HIGHEST-EVER REPORTED CDAI LDA RESPONSE OVER 6 MONTHS FULL CLINICAL AND TRANSLATIONAL DATA FOR ROSNILIMAB IN RA IN Q2 2025 TOP-LINE PHASE 2 DATA FOR ROSNILIMAB IN ULCERATIVE COLITIS (UC),MOVED UP TO Q4 2025 PHASE 1A TRIAL IN HEALTHY VOLUNTEERS ONGOING FOR ANB033, OUR CD122 ANTAGONIST, AND PHASE 1A TRIAL TO INITIATE THIS QUARTER FOR ANB101, OUR BDCA2 MODULATOR ANNOUNCED EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH VANDA PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONIST YEAR-END 2024 CASH AND INVESTMENTS OF ~$420 MILLION AND REITERATING CASH RUNWAY THROUGH YEAR-END 2027 SAN DIEGO, FEB. 27, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE. ROSNILIMAB'S POSITIVE PHASE 2B DATA IN RHEUMATOID ARTHRITIS HAS REVEALED IMPRESSIVE SAFETY, TOLERABILITY AND THREE-MONTH EFFICACY DATA THAT WAS SUSTAINED AND SURPASSES SIX-MONTH DATA FROM COMPETITOR ALL-ACTIVE, HEAD-TO-HEAD TRIALS.

ANAPTYS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 12 ON MEAN CHANGE FROM BASELINE DAS-28 CRP ACROSS ALL ROSNILIMAB DOSES VS. PLACEBO ACHIEVED STATISTICAL SIGNIFICANCE ON KEY SECONDARY ENDPOINTS AT WEEK 12 ON ACR20, ACR50 AND CDAI LDA DEMONSTRATED HIGHEST EVER REPORTED RESPONSES ON KEY SECONDARY ENDPOINTS AT WEEK 14 ON ACR20, ACR50, ACR70 AND CDAI LDA 69% OF ROSNILIMAB-TREATED PATIENTS ACHIEVED CDAI LDA AT WEEK 14 AND APPEAR TO SHOW SUSTAINED CDAI LDA AND ACR50 RESPONSES AND POTENTIALLY DEEPENING ACR70 RESPONSES OUT TO WEEK 28 ROBUST PHARMACOLOGICAL ACTIVITY OBSERVED IN REDUCTION OF PD-1HIGH T CELLS, INCREASE IN TOTAL TREGS AND REDUCTION OF CRP ACROSS ALL DOSES ROSNILIMAB WAS SAFE AND WELL TOLERATED WITH SIMILAR ADVERSE EVENT RATES VS.

ANAPTYS ANNOUNCES ROSNILIMAB ACHIEVED POSITIVE RESULTS IN RA PHASE 2B TRIAL AND HIGHEST EVER REPORTED CDAI LDA RESPONSE OVER 6 MONTHS

SAN DIEGO, FEB. 11, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, WILL HOST AN INVESTOR CALL AND LIVE WEBCAST TO REVIEW TOP-LINE DATA FROM THE GLOBAL PHASE 2B RENOIR CLINICAL TRIAL OF INVESTIGATIONAL ROSNILIMAB, A DEPLETER AND AGONIST OF PD-1+ T CELLS, FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS ON WEDNESDAY, FEB. 12, 2025, AT 8:30AM ET / 5:30AM PT.

ANAPTYS TO ANNOUNCE TOP-LINE DATA FROM PHASE 2B TRIAL OF ROSNILIMAB, A PD-1 DEPLETER AND AGONIST, IN RHEUMATOID ARTHRITIS ON FEB. 12, 2025

SAN DIEGO, FEB. 03, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT DANIEL FAGA, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ANAPTYS, WILL PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE ON WEDNESDAY, FEB. 5, 2025 AT 1:00PM ET / 10:00AM PT.

AnaptysBio, Inc.

ANAB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AnaptysBio, Inc.

ANAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANAB